Version 1
: Received: 19 October 2024 / Approved: 21 October 2024 / Online: 21 October 2024 (13:54:31 CEST)
How to cite:
Fankhauser, R.; Lu, A.; Kassim, A.; Biltibo, E. Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report. Preprints2024, 2024101597. https://doi.org/10.20944/preprints202410.1597.v1
Fankhauser, R.; Lu, A.; Kassim, A.; Biltibo, E. Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report. Preprints 2024, 2024101597. https://doi.org/10.20944/preprints202410.1597.v1
Fankhauser, R.; Lu, A.; Kassim, A.; Biltibo, E. Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report. Preprints2024, 2024101597. https://doi.org/10.20944/preprints202410.1597.v1
APA Style
Fankhauser, R., Lu, A., Kassim, A., & Biltibo, E. (2024). Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report. Preprints. https://doi.org/10.20944/preprints202410.1597.v1
Chicago/Turabian Style
Fankhauser, R., Adetola Kassim and Eden Biltibo. 2024 "Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report" Preprints. https://doi.org/10.20944/preprints202410.1597.v1
Abstract
We present a 53-year-old male with a history of relapsed refractory multiple myeloma (RRMM) with t(11;14) treated with venetoclax, carfilzomib and dexamethasone (VenKd), resulting in tumor lysis syndrome (TLS) with subsequent renal failure. Repeat marrow biopsy showed no monoclonal plasma cells but extensive fibrosis. Venetoclax was reintroduced after two months with marrow recovery. Venetoclax was titrated from 200 to 400 mg daily alongside IV fluids and allopurinol without TLS recurrence. Here, we highlight the importance of risk stratification, dose titration, and TLS prophylaxis with venetoclax use in RRMM.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.